Home > Journals > Esperienze Dermatologiche > Past Issues > Esperienze Dermatologiche 2018 June;20(2) > Esperienze Dermatologiche 2018 June;20(2):32-7

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   Freefree

Esperienze Dermatologiche 2018 June;20(2):32-7

DOI: 10.23736/S1128-9155.18.00475-2

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Complementary management of atopic dermatitis: a pilot study of a novel topical cream based on boswellic acids and glycyrrhetinic acid

Maria Rosaria CESARONE 1, Giada MARAMALDI 2 , Beatrice FERAGALLI 1, Shu HU 1, Gianni BELCARO 1, 3, Stefano TOGNI 2, Luca GIACOMELLI 4, Roberto EGGENHOFFNER 4

1 Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Chieti, Italy; 2 Indena S.p.A, Milan, Italy; 3 International Agency for Pharma Standard Supplements (IAPSS), London, UK; 4 Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy


PDF


BACKGROUND: This pilot study evaluates the feasibility of a novel topical formulation based on a proprietary delivery form of boswellic acid and 18-beta-glycyrrhetinic acid in the complementary management of patients with atopic dermatitis.
METHODS: The subjects were either managed with standard management (SM) alone or with SM plus a topical preparation containing a novel delivery form of boswellic acids and 18-β-glycyrrhetinic acid formulated with additional hydrating elements (including panthenol), the topical product (TP). Patients applied the cream twice a day for 4 weeks on all atopic sites. The assessments included the evaluation of clinical manifestations and objective measurements such as laser Doppler flux and in-situ oxidative stress.
RESULTS: Thirty-four patients were followed in a registry study; 16 patients were managed with SM and 18 with the new TP. At baseline, the two groups were comparable in terms of presence and severity of clinical manifestations. On the contrary, at 2 weeks, the group using the TP showed a significant reduction in the presence and severity of all clinical manifestations, in comparison with the group of patients using SM only. A decrease in skin oxidative stress was found in the group using the study product in comparison with the patients on SM. These positive results were further improved at 4 weeks.
CONCLUSIONS: The use of a cream with boswellic acids and 18-β-glycyrrhetinic acid allows an amelioration of the skin condition and may provide adjunctive benefits as restoring the skin barrier function, thus suggesting a supportive use in the remission phase, prolonging the remission times between clinical relapses with an overall improvement of the quality of life.


KEY WORDS: Boswellic acid - 18beta-glycyrrhetinic acid-3-O-beta-D-glucuronide - Topical administration - Skin cream - Pharmaceutics adjuvants - Atopic dermatitis

top of page